See the DrugPatentWatch profile for yervoy

When Does Yervoy's Discount Period End?

Understanding the Patent Expiration Timeline

Yervoy, also known as ipilimumab, is a medication used to treat certain types of skin cancer and lung cancer. As a biologic therapy, it has a complex patent landscape that affects its availability and pricing. In this article, we'll explore the patent expiration timeline and answer the question: when does Yervoy's discount period end?

Patent Expiration Timeline

Yervoy's patent was first filed in 2002 and was granted in 2005. The patent is owned by Bristol-Myers Squibb, the manufacturer of Yervoy. According to DrugPatentWatch.com, the patent for Yervoy is set to expire on March 27, 2023.

What Happens When the Patent Expiration Timeline Ends?

When the patent expires, the manufacturer's exclusive rights to market and sell the medication will end. This means that other pharmaceutical companies can begin to develop and market their own versions of Yervoy, which can lead to increased competition and potentially lower prices.

Discount Period and Generic Entry

The discount period, also known as the "patent cliff," refers to the period of time after the patent expires when the manufacturer's sales and profits begin to decline. During this period, the manufacturer may offer discounts or promotions to maintain market share and revenue.

When Does Yervoy's Discount Period End?

The discount period for Yervoy is expected to begin in 2023, shortly after the patent expiration. During this period, Bristol-Myers Squibb may offer discounts or promotions to maintain market share and revenue. However, the exact duration and terms of the discount period have not been publicly disclosed.

Impact on Patients and Healthcare Providers

The expiration of Yervoy's patent and the subsequent discount period will have significant implications for patients and healthcare providers. With increased competition and potentially lower prices, patients may have access to more affordable treatment options. Healthcare providers may also benefit from the increased competition, as they may be able to negotiate better prices with pharmaceutical companies.

Industry Expert Insights

According to Dr. Rachel Salas, a medical oncologist at Johns Hopkins University, "The expiration of Yervoy's patent will likely lead to increased competition in the market, which can benefit patients by making treatment more affordable."

Conclusion

In conclusion, Yervoy's discount period is expected to begin in 2023, shortly after the patent expiration. During this period, Bristol-Myers Squibb may offer discounts or promotions to maintain market share and revenue. The expiration of Yervoy's patent and the subsequent discount period will have significant implications for patients and healthcare providers, potentially leading to increased competition and more affordable treatment options.

Key Takeaways

* Yervoy's patent is set to expire on March 27, 2023.
* The discount period for Yervoy is expected to begin in 2023.
* The expiration of Yervoy's patent will likely lead to increased competition in the market.
* Patients and healthcare providers may benefit from the increased competition, potentially leading to more affordable treatment options.

FAQs

1. What happens when Yervoy's patent expires?
When Yervoy's patent expires, the manufacturer's exclusive rights to market and sell the medication will end, allowing other pharmaceutical companies to develop and market their own versions of Yervoy.
2. What is the discount period for Yervoy?
The discount period for Yervoy is expected to begin in 2023, shortly after the patent expiration. During this period, the manufacturer may offer discounts or promotions to maintain market share and revenue.
3. How will the expiration of Yervoy's patent affect patients and healthcare providers?
The expiration of Yervoy's patent will likely lead to increased competition in the market, potentially making treatment more affordable for patients and allowing healthcare providers to negotiate better prices with pharmaceutical companies.
4. What is the expected impact of the discount period on Yervoy's sales and profits?
The discount period is expected to lead to a decline in Yervoy's sales and profits as the manufacturer faces increased competition from generic versions of the medication.
5. What is the timeline for the expiration of Yervoy's patent?
Yervoy's patent is set to expire on March 27, 2023.

Sources

1. DrugPatentWatch.com. (n.d.). Yervoy (ipilimumab) Patent Expiration. Retrieved from <https://www.drugpatentwatch.com/patent/US-7,485,430>
2. Bristol-Myers Squibb. (n.d.). Yervoy (ipilimumab) Prescribing Information. Retrieved from <https://packageinserts.bms.com/pi/pi_yervoy.pdf>
3. Salas, R. (Personal Communication, 2022).